Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/91111/1/phco.30.3.265.pd
Rationale: The P2Y12receptor inhibitor clopidogrel is widely used in patients with acute coronary sy...
Dual-antiplatelet treatment with aspirin and clopidogrel is the recommended therapy for prevention o...
The capacity of clopidogrel to inhibit ADP-induced platelet aggregation shows wide intersubjectvaria...
Clopidogrel, the top prescribed antiplatelet medication for individuals who have experienced a myoca...
Antiplatelet agents are the mainstay treatment in the prevention and management of atherothrombotic...
Introduction Clopidogrel is a P2Y12 inhibitor that has become a mainstay treatment following percuta...
Increasing evidence for the role of pharmacogenetics in treatment resistance to the antiplatelet age...
Objectives: Antiplatelet therapy with either clopidogrel alone or in combination with aspirin is the...
Clopidogrel is a pro-drug which is converted to an active metabolite that selectively blocks ADP-dep...
The CYP2C19*2 genetic variant is known to contribute to low responsiveness to clopidogrel treatment,...
Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated with adve...
Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated with adve...
Background and objective: Additional loading doses and higher maintenance doses (MDs) have been used...
Dual-antiplatelet treatment with aspirin and clopidogrel is the recommended therapy for prevention o...
RATIONALE The P2Y receptor inhibitor clopidogrel is widely used in patients with acute coronary s...
Rationale: The P2Y12receptor inhibitor clopidogrel is widely used in patients with acute coronary sy...
Dual-antiplatelet treatment with aspirin and clopidogrel is the recommended therapy for prevention o...
The capacity of clopidogrel to inhibit ADP-induced platelet aggregation shows wide intersubjectvaria...
Clopidogrel, the top prescribed antiplatelet medication for individuals who have experienced a myoca...
Antiplatelet agents are the mainstay treatment in the prevention and management of atherothrombotic...
Introduction Clopidogrel is a P2Y12 inhibitor that has become a mainstay treatment following percuta...
Increasing evidence for the role of pharmacogenetics in treatment resistance to the antiplatelet age...
Objectives: Antiplatelet therapy with either clopidogrel alone or in combination with aspirin is the...
Clopidogrel is a pro-drug which is converted to an active metabolite that selectively blocks ADP-dep...
The CYP2C19*2 genetic variant is known to contribute to low responsiveness to clopidogrel treatment,...
Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated with adve...
Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated with adve...
Background and objective: Additional loading doses and higher maintenance doses (MDs) have been used...
Dual-antiplatelet treatment with aspirin and clopidogrel is the recommended therapy for prevention o...
RATIONALE The P2Y receptor inhibitor clopidogrel is widely used in patients with acute coronary s...
Rationale: The P2Y12receptor inhibitor clopidogrel is widely used in patients with acute coronary sy...
Dual-antiplatelet treatment with aspirin and clopidogrel is the recommended therapy for prevention o...
The capacity of clopidogrel to inhibit ADP-induced platelet aggregation shows wide intersubjectvaria...
DOI
Add to ORKG